companydata.dkAmicus Therapeutics ApS: Financial statements 2019
CVR: 39359340
Amicus Therapeutics ApS (CVR 39359340) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 2,019,085 and a net result of DKK 84,291 compared with DKK 73,533 the year before. That is an increase of 2% compared with the year before. Equity amounted to DKK 207,824. The solvency ratio was 41.8%. The company had 2 employees in the financial year.
- Gross Profit
- 2,019,085 kr.
- Profit/Loss
- 84,291 kr.
- Equity
- 207,824 kr.
- Total Assets
- 496,746 kr.
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 2 mio. | 84 t. | 208 t. | 2 |
| 2018 | - | 2 mio. | 74 t. | 124 t. | 2 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
Amicus Therapeutics ApS has published its interim report for the period February 23, 2018 – December 31, 2018.
As of February 12, 2019, Detlef Wolff has left the board of directors of Amicus Therapeutics ApS.
About Amicus Therapeutics ApS
Amicus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Richard Gideon Morris. The company is owned by Amicus Therapeutics UK Ltd.. The company has 2 employees. In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. Equity amounted to DKK 424,641.